Author

Shunsuke Ebara

Observed names: Ebara, Shunsuke, S Ebara

Institution: Chordia Therapeutics Inc. (Japan)

Observed institutions: Chordia Therapeutics Inc. (Japan), Takeda (Japan), Ibaraki University

ORCID: 0000-0001-6057-6173

Observed ORCID: 0000-0001-6057-6173

OpenAlex ID: A5017799711

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

2018 · Akito Nakamura, Tadahiro Nambu, et al. · Proceedings of the National Academy of Sciences · 185

Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions

2017 · S Murai, A Ando, et al. · Oncogenesis · 88

PDF

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

2019 · Kenichi Iwai, Tadahiro Nambu, et al. · Science Advances · 67

CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells

2018 · Akito Nakamura, Daisuke Nakata, et al. · Oncotarget · 52

PDF

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors

2017 · Satoshi Kitazawa, Shunsuke Ebara, et al. · Oncotarget · 35

PDF

Panitumumab interaction with TAS ‐102 leads to combinational anticancer effects via blocking of EGFR ‐mediated tumor response to trifluridine

2017 · Yuji Baba, Toshiya Tamura, et al. · Molecular Oncology · 24

PDF

Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors

2020 · Aiko Murai, Shunsuke Ebara, et al. · PLoS ONE · 18

PDF

CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockade

2026 · Hiroko Yamakawa, Raghda Khatab, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4

PDF

A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma

2026 · Shunsuke Kawahara, Mana Taki, et al. · Molecular Cancer Therapeutics · 3

Mutations in the FHA-domain of ectopically expressed NBS1 lead to radiosensitization and to no increase in somatic mutation rates via a partial suppression of homologous recombination

2014 · Maki Ohara, Yumi Funyu, et al. · Journal of Radiation Research · 3

PDF

Abstract 1745: Combining HRI/PERK/GCN2 inhibitor CRD-799 with proteasome inhibitors provides a novel approach to overcoming resistance in multiple myeloma treatment

2025 · Yasumichi Inoue, Koki Hikami, et al. · Cancer Research · 2

Abstract 3301: Translational research of CDK12/13 inhibitor, CTX-439, informing clinical trial strategy

2024 · Hiroko Yamakawa, Shunsuke Ebara, et al. · Cancer Research · 2

Phosphorylation Dynamics and Kinase Interaction in mRNA Transcription-Associated Kinases: Autophosphorylation of CDK12 and its Modulation by CDK7 and CDK9

2024 · Hiroko Yamakawa, Shunsuke Ebara, et al. · BPB Reports · 2

PDF

Abstract 5485: Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor

2022 · Hiroko Yamakawa, Akio Mizutani, et al. · Cancer Research · 2

Abstract 1636: Novel CDK12/13 inhibitor CTX-439 downregulates MCL1 via transcriptional mRNA read-through and synergistically acts with BCL-XL inhibitors for cancer therapy

2025 · Hiroko Yamakawa, Raghda Khatab, et al. · Cancer Research · 1

Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA

2024 · Shunsuke Ebara, Misaki Yoshida, et al. · Biochemical and Biophysical Research Communications · 1

PDF

Abstract 1233: Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma

2024 · Yasumichi Inoue, Koki Hikami, et al. · Cancer Research · 1

Abstract 5389: Exploring potential predictive biomarkers for the responsiveness to CTX-712 by in vivo drug sensitivity analysis on PDX models

2022 · Daisuke Morishita, Shigehiro Yagishita, et al. · Cancer Research · 1

Supplementary Figure S6 from A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma